Ocular Pain
4
Pipeline Programs
2
Companies
4
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
2
1
1
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
2 companies ranked by most advanced pipeline stage
SylentisSpain - Madrid
3 programs1
1
1
SYL1001Phase 21 trial
SYL1001Phase 1/21 trial
SYL1001Phase 11 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
SylentisSYL1001
SylentisSYL1001
Bausch + LombBL1332 ophthalmic solution
SylentisSYL1001
Clinical Trials (4)
Total enrollment: 24 patients across 4 trials
Dose-finding Study to Assess the Safety and Effect of SYL1001 in Patients With Ocular Pain
Start: Jun 2015
Phase 2Completed
Pilot Study to Evaluate SYL1001 Safety and Effect in Patients With Ocular Pain
Start: Nov 2012
Phase 1/2Completed
A Study to Assess Safety, Tolerability, and Pharmacokinetics of Ascending Concentrations of Topical Ocular BL1332 in Healthy Volunteers
Start: Jul 2025Est. completion: Nov 202624 patients
Phase 1Active Not Recruiting
Study to Evaluate the Ocular Tolerance of SYL1001 in Healthy Volunteers
Start: Jul 2011Est. completion: Jun 2012
Phase 1Completed
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
2 companies competing in this space